HUNT VALLEY, Md.--(BUSINESS WIRE)--April 25, 2006--CepTor Corporation (OTC BB:CEPO - News), a development-stage biopharmaceutical company focusing on cell-targeted therapeutic products for neuromuscular and neurodegenerative diseases, in a platform presentation delivered at the recent AAN meeting in San Diego, presented proof of concept data for its targeted calpain inhibiting drug, Myodur, in Duchenne Muscular Dystrophy (DMD). In the mdx mouse, an animal model with a genetic defect identical to DMD, the company showed muscle tissue preservation on histopathology and a statistically significant increase in myofiber (muscle fibers) diameter in treated vs non-treated mice. DMD is a fatal muscle wasting disease caused by abnormally high levels of calpain activity. The Company also presented data demonstrating the efficiency of its cell targeted technology through in-vitro studies in human cell lines showing that its calpain inhibitor is 50-100 times more potent when targeted with a carnitine carrier compared to when delivered alone. Importantly, the company also presented information involving the development of a biomarker that can specifically measure excess calpain activity.
